There has been a surge in cannabidiol (CBD) products on the market as of late. The FDA has stated that they feel the need for a new regulatory pathway, to balance individuals desire for access with the oversight needed to manage risks.
CBD is the second most prevalent active ingredient in marijuana. Animal studies, as well as self-reports or research in humans suggest that it has its benefits such as reducing anxiety, helping with insomnia, as well as chronic pain associated with inflammation due to arthritis, according to Harvard Health Publishing.
The FDA says studies suggest that CBD has potential side effects after long-term use such as potential liver damage, interactions with certain medications, and possible harm to the male reproductive system. There are also concerns about its effect on pregnant women.
The FDA says they will continue to take action against CBD and other cannabis-based products to protect the public when appropriate, and looks forward to working with Congress on a regulation strategy.
Reporting for WGRT – Choze Powell
